ATCC^®ウェビナーのお知らせ
「HCMI作製の次世代がんモデル665種の臨床・分子的特性の統合的な解析」

Dina ElHarouni, PhD（Postdoctoral Research Fellow, Dana-Farber Cancer Institute）

Dina ElHarouni is a postdoctoral research fellow at the Dana-Farber Cancer Institute, and the Broad Institute of MIT and Harvard, specializing in computational oncology and functional precision medicine. She earned her PhD in Clinical Bioinformatics from the German Cancer Research Center (DKFZ), where she focused on therapy response scoring and identifying multi-omics biomarkers to advance precision treatments for pediatric solid tumors. Her work bridges computational models and clinical applications, with the goal of developing personalized treatment strategies through data-driven insights. In recognition of her contributions to computational oncology, Dina was selected to attend the 70th Lindau Nobel Laureates Meeting in 2020/2021 and became a member of the Lindau Alumni Young Scientists community. In 2025, she was awarded the Women in Cancer Research (WICR) Scholar Award from the American Association for Cancer Research (AACR^®). At Dana-Farber, Dina continues to push the boundaries of precision medicine by integrating computational approaches with functional assays, aiming to transform how patient-derived models inform clinical decision-making. She also co-leads efforts within the Human Cancer Models Initiative (HCMI) to develop, characterize, and apply next-generation patient-derived models as an open resource for the global research community.

Andrew McPherson, PhD,（Assistant Attending, Computational Oncologist, Memorial Sloan Kettering Cancer Center）

Assistant Attending, Computational Oncologist, Memorial Sloan Kettering Cancer Center Andrew McPherson is an Assistant Attending Computational Oncologist in the Department of Epidemiology and Biostatistics and a faculty member of Computational Oncology. Andrew’s research focuses on computational methods for analysis of single cell genomic data, with specific focus on understanding genomic instability, mutational processes, clonal evolution and the role of the microenvironment in cancer development and progression. During his doctoral research, Dr. McPherson developed methods for cancer genome sequence analysis, including detection and characterization of genome rearrangements, and inference of clonal phylogenies. Dr. McPhersons post-doctoral research at University of British Columbia focused on the development of computational methods and infrastructure for a novel single cell whole genome sequencing (scWGS) platform, Direct Library Preparation. During his time at MSKCC, Dr. McPherson has led efforts to establish a production implementation of scWGS via DLP within MSKCC, and support use of the platform through collaborations with investigators throughout the institute. In addition, Dr. McPherson has contributed to several large scale single cell genomics studies of Breast and Ovarian cancer.

Abhay U. Andar, PhD,（Lead Scientist, Microphysiological Systems, ATCC^®）

Dr. Abhay U. Andar has over 13 years of experience in translational oncology, microfluidics, and advanced in vitro disease modeling. At ATCC^®, Dr. Andar leads the Human Cancer Model Initiative (HCMI) portfolio, which includes over 300 patient-derived cancer models spanning 28 indications. His research focuses on developing organoid systems to support therapeutic discovery and translational research in oncology. Dr. Andar earned his Ph.D. and M.Sc. in Biomedical Science and Engineering from the University of Glasgow, and a B.Sc. in Life Sciences from the University of Mumbai. He has authored numerous publications and patents in cancer research, microfluidics, and therapeutic manufacturing, with work featured in Nature Materials, Nature Biomedical Engineering, Lab on Chip, Cancer Research, and Biotechnology and Bioengineering. Dr. Andar’s innovations in Tumor-on-Chip platforms, organoid generation, and immune co-culture systems continue to shape the future of personalized medicine and drug discovery.